Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Duke Energy targets 5%-7% EPS CAGR through 2025 » 16:53
06/11/21
06/11
16:53
06/11/21
16:53
DUK

Duke Energy

$101.93 /

+0.24 (+0.24%)

Off 2021 midpoint of…

Off 2021 midpoint of $5.15. Says "on track" to achieve 2021 adjusted EPS guidance of $5.00-$5.30, consensus $5.18. Sees 2021-2025 CapEx $59B; 2025-2029 CapEx $65B-$75B. Says no common equity issuances in 5-year plan. Guidance taken from investor presentation slides.

ShowHide Related Items >><<
DUK Duke Energy
$101.93 /

+0.24 (+0.24%)

DUK Duke Energy
$101.93 /

+0.24 (+0.24%)

05/18/21 Morgan Stanley
Morgan Stanley sees 'low probability' Duke Energy and Elliott reach agreement
05/12/21 Mizuho
Duke Energy price target raised to $105 from $96 at Mizuho
04/14/21 Credit Suisse
Duke Energy price target raised to $104 from $96 at Credit Suisse
04/14/21 Wells Fargo
Duke Energy price target raised to $104 from $97 at Wells Fargo
DUK Duke Energy
$101.93 /

+0.24 (+0.24%)

DUK Duke Energy
$101.93 /

+0.24 (+0.24%)

DUK Duke Energy
$101.93 /

+0.24 (+0.24%)

Hot Stocks
Novavax reports 'positive' data from COVID-19 Beta variant vaccine studies » 16:06
06/11/21
06/11
16:06
06/11/21
16:06
NVAX

Novavax

$209.60 /

+5.03 (+2.46%)

Novavax announced…

Novavax announced preclinical and clinical data on the company's recombinant protein COVID-19 vaccine candidate, NVX-CoV2373, directed against the SARS-CoV-2 Beta variant, which was originally identified in South Africa. The data show that the vaccine demonstrated strong immunogenicity and protection against both the Alpha variant, which was originally identified in the United Kingdom, and the Beta variant as well as the original SARS-CoV-2 in animal and human studies. "While current vaccines are effective against selected SARS-CoV-2 variant strains, newly emerging variants are also being identified that have the ability to overcome vaccine induced immunity," said Matthew Frieman, PhD, Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine, who collaborated on these studies. "This work demonstrates that variant vaccines that protect against these newly emerging variants have the potential to be highly effective and may produce broader protection against variants we know of and those that will arise in the future. Clinical trials will provide further evidence on the effectiveness of variant vaccines." The studies compared the Beta-directed vaccine to Novavax' prototype vaccine candidate as standalone, in combination, and as heterologous prime boost vaccine. The findings show a broad array of cellular and humoral responses in animal models against all virus strains evaluated. The Alpha and Beta variant strains have created public health concerns due to increased transmission rates and lower efficacy of current vaccines seen against Beta. Novavax expects to initiate further clinical testing of rS-B.1.351 in the fall of 2021.

ShowHide Related Items >><<
NVAX Novavax
$209.60 /

+5.03 (+2.46%)

NVAX Novavax
$209.60 /

+5.03 (+2.46%)

06/07/21 B. Riley
Novavax risk/reward attractive into Covid vaccine data, says B. Riley
05/12/21
Fly Intel: Top five analyst downgrades
05/12/21 B. Riley
Novavax price target lowered to $286 from $365 at B. Riley
05/12/21 Cantor Fitzgerald
Novavax price target lowered to $217 from $338 at Cantor Fitzgerald
NVAX Novavax
$209.60 /

+5.03 (+2.46%)

NVAX Novavax
$209.60 /

+5.03 (+2.46%)

NVAX Novavax
$209.60 /

+5.03 (+2.46%)

NVAX Novavax
$209.60 /

+5.03 (+2.46%)

Periodicals
Facebook says work from home policy could slow Irish jobs growth, Reuters says » 12:12
06/11/21
06/11
12:12
06/11/21
12:12
FB

Facebook

$329.72 /

-2.84 (-0.85%)

Facebook's Ireland…

Facebook's Ireland chief Gareth Lambe said that the company still intends to "aggressively" grow employee numbers in its European headquarters in Ireland, though he noted that a company-wide policy allowing permanent remote work from other countries could hamper growth over time, Reuters' Padraic Halpin reports. Lambe said the company was still working out how many Irish-based staff would be eligible to take advantage of the policy, the author says, noting that fewer than half the unit's staff are Irish nationals. "We're going to continue to grow aggressively," he told national broadcaster RTE. "This won't have on balance a material impact on the growth of employment for Facebook in Ireland," Lambe added, referring to the remote working policy. "We have a target this year of adding about an additional 700 employees and we're going to continue to do that and we're going to continue to grow." Reference Link

ShowHide Related Items >><<
FB Facebook
$329.72 /

-2.84 (-0.85%)

FB Facebook
$329.72 /

-2.84 (-0.85%)

06/08/21 Tigress Financial
Tigress sees Facebook shares going to $430 within 12 months
06/08/21 Wedbush
Apple WWDC 'all about iOS 15, new Macs,' says Wedbush
06/03/21 Jefferies
Facebook building 'comprehensive SMB tool-set,' says Jefferies
06/03/21 Wedbush
Wedbush expects data privacy to be main focus of Apple's Cook keynote address
FB Facebook
$329.72 /

-2.84 (-0.85%)

FB Facebook
$329.72 /

-2.84 (-0.85%)

FB Facebook
$329.72 /

-2.84 (-0.85%)

FB Facebook
$329.72 /

-2.84 (-0.85%)

Hot Stocks
EMA recommends Pfizer's Xeljanz only be used in patients over 65 » 11:30
06/11/21
06/11
11:30
06/11/21
11:30
PFE

Pfizer

$40.04 /

-0.65 (-1.60%)

Pfizer announced that the…

Pfizer announced that the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency has recommended that Xeljanz should only be used in patients over 65 years of age, patients who are current or past smokers, patients with other cardiovascular risk factors, and patients with other malignancy risk factors, if no suitable treatment alternative is available. The recommendation is based on the receipt of data from the post-marketing requirement study ORAL Surveillance in rheumatoid arthritis patients, Pfizer said in a statement.

ShowHide Related Items >><<
PFE Pfizer
$40.04 /

-0.65 (-1.60%)

PFE Pfizer
$40.04 /

-0.65 (-1.60%)

06/07/21 BofA
BofA upgrades Biogen to Neutral with $400 price target after Aduhelm approved
06/01/21 Argus
Argus says market underestimating sustainability of Pfizer COVID vaccine program
05/18/21 William Blair
William Blair says continued lack of '9001 safety signals positive for Sarepta
05/12/21 Canaccord
BioNTech price target raised to $240 from $130 at Canaccord
PFE Pfizer
$40.04 /

-0.65 (-1.60%)

PFE Pfizer
$40.04 /

-0.65 (-1.60%)

PFE Pfizer
$40.04 /

-0.65 (-1.60%)

PFE Pfizer
$40.04 /

-0.65 (-1.60%)

Periodicals
Amazon, tech peers could be forced to shed assets under new bill, WSJ says » 11:00
06/11/21
06/11
11:00
06/11/21
11:00
AMZN

Amazon.com

$3,346.50 /

-3.58 (-0.11%)

, AAPL

Apple

$126.80 /

+0.7 (+0.56%)

, FB

Facebook

$329.61 /

-2.95 (-0.89%)

, GOOGL

Alphabet Class A

$2,421.00 /

-14.68 (-0.60%)

, GOOG

Alphabet

$2,499.57 /

-22.45 (-0.89%)

House lawmakers are…

House lawmakers are preparing to propose bipartisan legislation, which could be announced Friday, that may require Amazon (AMZN) and other technology giants to effectively split into two companies or shed their private-label products, according to The Wall Street Journal's Dana Mattioli and Ryan Tracy, citing people familiar with the matter. Another bill that also could be announced Friday targets the ability of big tech companies to leverage their online platforms to favor their own products over competitors and is among five bills under consideration that aim to curb the dominance of Amazon as well as other tech giants including Apple (AAPL), Facebook (FB) and Alphabet's (GOOGL) Google, the report said. Reference Link

ShowHide Related Items >><<
GOOGL Alphabet Class A
$2,421.00 /

-14.68 (-0.60%)

FB Facebook
$329.61 /

-2.95 (-0.89%)

AMZN Amazon.com
$3,346.50 /

-3.58 (-0.11%)

AAPL Apple
$126.80 /

+0.7 (+0.56%)

AMZN Amazon.com
$3,346.50 /

-3.58 (-0.11%)

06/08/21 Piper Sandler
New Amazon offering targets Hims & Hers and others, says Piper Sandler
06/08/21 UBS
Snowflake price target raised to $300 from $275 at UBS
06/07/21 Loop Capital
Best Buy prices remain 'very competitive' to Amazon's, says Loop Capital
06/07/21 Roth Capital
iPower initiated with a Buy at Roth Capital
AAPL Apple
$126.80 /

+0.7 (+0.56%)

06/11/21 Argus
Apple underperformance due to sector rotation, not misfires, says Argus
06/08/21 RBC Capital
Fisker initiated with an Outperform at RBC Capital
06/08/21 BofA
Apple App store growth decelerating in Q3 to-date, says BofA
06/08/21 Wedbush
Apple WWDC 'all about iOS 15, new Macs,' says Wedbush
FB Facebook
$329.61 /

-2.95 (-0.89%)

06/08/21 Tigress Financial
Tigress sees Facebook shares going to $430 within 12 months
06/03/21 Jefferies
Facebook building 'comprehensive SMB tool-set,' says Jefferies
06/03/21 Wedbush
Wedbush expects data privacy to be main focus of Apple's Cook keynote address
GOOGL Alphabet Class A
$2,421.00 /

-14.68 (-0.60%)

06/11/21 Tigress Financial
Tigress sees Alphabet shares rising to $3,185 in 12 months
06/02/21 KGI Securities
Alphabet initiated with an Outperform at KGI Securities
05/20/21 Credit Suisse
I/O showcases Google's sprawling footprint, says Credit Suisse
GOOG Alphabet
$2,499.57 /

-22.45 (-0.89%)

05/19/21 JPMorgan
Broadcom continues to win AI chip work at Google, says JPMorgan
05/19/21 KeyBanc
Google I/O reinforces AI experience improvement across products, says KeyBanc
GOOGL Alphabet Class A
$2,421.00 /

-14.68 (-0.60%)

FB Facebook
$329.61 /

-2.95 (-0.89%)

AMZN Amazon.com
$3,346.50 /

-3.58 (-0.11%)

AAPL Apple
$126.80 /

+0.7 (+0.56%)

GOOGL Alphabet Class A
$2,421.00 /

-14.68 (-0.60%)

FB Facebook
$329.61 /

-2.95 (-0.89%)

AMZN Amazon.com
$3,346.50 /

-3.58 (-0.11%)

AAPL Apple
$126.80 /

+0.7 (+0.56%)

GOOGL Alphabet Class A
$2,421.00 /

-14.68 (-0.60%)

FB Facebook
$329.61 /

-2.95 (-0.89%)

AMZN Amazon.com
$3,346.50 /

-3.58 (-0.11%)

AAPL Apple
$126.80 /

+0.7 (+0.56%)

GOOGL Alphabet Class A
$2,421.00 /

-14.68 (-0.60%)

GOOG Alphabet
$2,499.57 /

-22.45 (-0.89%)

FB Facebook
$329.61 /

-2.95 (-0.89%)

AMZN Amazon.com
$3,346.50 /

-3.58 (-0.11%)

AAPL Apple
$126.80 /

+0.7 (+0.56%)

Initiation
Fly Intel: Top five analyst initiations » 09:54
06/11/21
06/11
09:54
06/11/21
09:54
VXRT

Vaxart

$8.05 /

+0.88 (+12.27%)

, NDAQ

Nasdaq

$172.08 /

+3.75 (+2.23%)

, NTLA

Intellia Therapeutics

$84.00 /

+0.79 (+0.95%)

, GPOR

Gulfport Energy

$64.88 /

+0.89 (+1.39%)

, TENB

Tenable Holdings

$43.17 /

+0.19 (+0.44%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Vaxart (VXRT) initiated with an Overweight at Piper Sandler. 2. Nasdaq (NDAQ) initiated with an Overweight at Morgan Stanley. 3. Intellia Therapeutics (NTLA) initiated with a Buy at H.C. Wainwright. 4. Gulfport Energy (GPOR) initiated with a Buy at Truist. 5. Tenable Holdings (TENB) initiated with a Buy at Needham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
VXRT Vaxart
$8.05 /

+0.88 (+12.27%)

TENB Tenable Holdings
$43.17 /

+0.19 (+0.44%)

NTLA Intellia Therapeutics
$84.00 /

+0.79 (+0.95%)

NDAQ Nasdaq
$172.08 /

+3.75 (+2.23%)

GPOR Gulfport Energy
$64.88 /

+0.89 (+1.39%)

VXRT Vaxart
$8.05 /

+0.88 (+12.27%)

06/11/21 Piper Sandler
Vaxart initiated with an Overweight at Piper Sandler
03/04/21 B. Riley
Vaxart price target lowered to $13 from $16 at B. Riley Securities
11/18/20 B. Riley
Vaxart price target lowered to $16 from $22 at B. Riley Securities
10/13/20 B. Riley
B. Riley views Vaxart as key player in 'second wave' of Covid vaccines
NDAQ Nasdaq
$172.08 /

+3.75 (+2.23%)

06/11/21 Morgan Stanley
Nasdaq initiated with an Overweight at Morgan Stanley
04/22/21 Wells Fargo
Nasdaq price target raised to $186 from $173 at Wells Fargo
04/22/21 Oppenheimer
Nasdaq price target raised to $182 from $170 at Oppenheimer
04/22/21 Barclays
Nasdaq price target raised to $175 from $165 at Barclays
NTLA Intellia Therapeutics
$84.00 /

+0.79 (+0.95%)

06/11/21 H.C. Wainwright
Intellia Therapeutics initiated with a Buy at H.C. Wainwright
05/07/21 Roth Capital
Intellia Therapeutics upgraded to Buy from Neutral at Roth Capital
05/07/21 Roth Capital
Intellia Therapeutics upgraded to Buy from Neutral at Roth Capital
05/03/21 RBC Capital
Intellia Therapeutics initiated with an Outperform at RBC Capital
GPOR Gulfport Energy
$64.88 /

+0.89 (+1.39%)

06/11/21 Truist
Gulfport Energy initiated with a Buy at Truist
06/11/21 Truist
Gulfport Energy initiated with a Buy at Truist
TENB Tenable Holdings
$43.17 /

+0.19 (+0.44%)

06/11/21 Needham
Needham starts Tenable Holdings at Buy, sees FY22 payoff from investment year
06/11/21 Needham
Tenable Holdings initiated with a Buy at Needham
05/19/21 Stifel
Tenable the best way to gain exposure to ICS/OT security spending, says Stifel
05/10/21 Goldman Sachs
FireEye could be direct beneficiary of pipeline cyberattack, says Goldman Sachs
VXRT Vaxart
$8.05 /

+0.88 (+12.27%)

TENB Tenable Holdings
$43.17 /

+0.19 (+0.44%)

NTLA Intellia Therapeutics
$84.00 /

+0.79 (+0.95%)

NDAQ Nasdaq
$172.08 /

+3.75 (+2.23%)

  • 02
    Dec
  • 31
    Jul
VXRT Vaxart
$8.05 /

+0.88 (+12.27%)

NDAQ Nasdaq
$172.08 /

+3.75 (+2.23%)

VXRT Vaxart
$8.05 /

+0.88 (+12.27%)

TENB Tenable Holdings
$43.17 /

+0.19 (+0.44%)

NDAQ Nasdaq
$172.08 /

+3.75 (+2.23%)

VXRT Vaxart
$8.05 /

+0.88 (+12.27%)

Recommendations
Tigress sees Alphabet shares rising to $3,185 in 12 months » 09:24
06/11/21
06/11
09:24
06/11/21
09:24
GOOG

Alphabet

$2,522.63 /

+30.04 (+1.21%)

, GOOGL

Alphabet Class A

$2,435.14 /

+26.44 (+1.10%)

Tigress Financial analyst…

Tigress Financial analyst Ivan Feinseth reiterates a Strong Buy rating on Alphabet and initiates a 12-month target price of $3,185, which represents a potential return of over 30% from current levels. Accelerating growth in online advertising and spending, along with increasing cloud growth and margin expansion, will continue to drive further share price gains, Feinseth tells investors in a research note. The analyst says Alphabet continues to benefit from the ongoing secular shift to digital advertising and online spending.

ShowHide Related Items >><<
GOOG Alphabet
$2,522.63 /

+30.04 (+1.21%)

GOOG Alphabet
$2,522.63 /

+30.04 (+1.21%)

06/02/21 KGI Securities
Alphabet initiated with an Outperform at KGI Securities
05/19/21 JPMorgan
Broadcom continues to win AI chip work at Google, says JPMorgan
05/19/21 KeyBanc
Google I/O reinforces AI experience improvement across products, says KeyBanc
05/10/21
Fly Intel: Top five analyst downgrades
GOOGL Alphabet Class A
$2,435.14 /

+26.44 (+1.10%)

06/08/21 UBS
Snowflake price target raised to $300 from $275 at UBS
05/20/21 Credit Suisse
I/O showcases Google's sprawling footprint, says Credit Suisse
GOOG Alphabet
$2,522.63 /

+30.04 (+1.21%)

GOOG Alphabet
$2,522.63 /

+30.04 (+1.21%)

GOOG Alphabet
$2,522.63 /

+30.04 (+1.21%)

GOOGL Alphabet Class A
$2,435.14 /

+26.44 (+1.10%)

GOOG Alphabet
$2,522.63 /

+30.04 (+1.21%)

Recommendations
Magnite partnerships can help accelerate shift in spend to CTV, says Stephens » 08:07
06/11/21
06/11
08:07
06/11/21
08:07
MGNI

Magnite

$32.55 /

-1.31 (-3.87%)

, TTD

Trade Desk

$589.71 /

+4.56 (+0.78%)

Stephens analyst Nicholas…

Stephens analyst Nicholas Zangler said he like Magnite's (MGNI) recently announced IRIS.TV and tvScientific partnerships, which he thinks can help accelerate the "inevitable shift in ad spend" from linear TV and search/social into the Connected TV segment. The analyst, who believes that over time "virtually all linear TV advertising will be converted to CTV," keeps a Buy rating and $48 price target on Magnite shares, but argues the stock "would be trading at $60" if it was awarded the multiple granted to Trade Desk (TTD).

ShowHide Related Items >><<
TTD Trade Desk
$589.71 /

+4.56 (+0.78%)

MGNI Magnite
$32.55 /

-1.31 (-3.87%)

MGNI Magnite
$32.55 /

-1.31 (-3.87%)

06/07/21
Fly Intel: Top five analyst upgrades
06/07/21 Truist
Magnite upgraded to Buy from Hold at Truist
05/25/21 Susquehanna
Magnite CTV weakness a symptom of its small base, says Susquehanna
05/11/21 Craig-Hallum
Magnite price target lowered to $50 from $72 at Craig-Hallum
TTD Trade Desk
$589.71 /

+4.56 (+0.78%)

05/11/21
Fly Intel: Top five analyst upgrades
05/11/21 Wells Fargo
Trade Desk price target lowered to $750 from $1,000 at Wells Fargo
05/11/21 KeyBanc
Trade Desk price target lowered to $740 from $851 at KeyBanc
05/11/21 Oppenheimer
Trade Desk price target lowered to $600 from $950 at Oppenheimer
TTD Trade Desk
$589.71 /

+4.56 (+0.78%)

MGNI Magnite
$32.55 /

-1.31 (-3.87%)

TTD Trade Desk
$589.71 /

+4.56 (+0.78%)

MGNI Magnite
$32.55 /

-1.31 (-3.87%)

TTD Trade Desk
$589.71 /

+4.56 (+0.78%)

MGNI Magnite
$32.55 /

-1.31 (-3.87%)

TTD Trade Desk
$589.71 /

+4.56 (+0.78%)

MGNI Magnite
$32.55 /

-1.31 (-3.87%)

Initiation
Needham starts Tenable Holdings at Buy, sees FY22 payoff from investment year » 07:36
06/11/21
06/11
07:36
06/11/21
07:36
TENB

Tenable Holdings

$42.98 /

+0.72 (+1.70%)

As previously reported,…

As previously reported, Needham analyst Mike Cikos initiated coverage of Tenable Holdings with a Buy rating and $51 price target. The company offers "differentiated strategy" toward reducing the "CyberExposure Gap", while its recently acquired Alsid presents a unique asset that will expand its total addressable market, the analyst tells investors in a research note. Cikos adds that 2021 is an "investing year" for Tenable, but he expects its revenue growth in 2022 to accelerate from the 18%-19% this year.

ShowHide Related Items >><<
TENB Tenable Holdings
$42.98 /

+0.72 (+1.70%)

TENB Tenable Holdings
$42.98 /

+0.72 (+1.70%)

06/11/21 Needham
Tenable Holdings initiated with a Buy at Needham
05/19/21 Stifel
Tenable the best way to gain exposure to ICS/OT security spending, says Stifel
05/10/21 Goldman Sachs
FireEye could be direct beneficiary of pipeline cyberattack, says Goldman Sachs
02/22/21 Barclays
Tenable Holdings initiated with an Overweight at Barclays
TENB Tenable Holdings
$42.98 /

+0.72 (+1.70%)

  • 31
    Jul
TENB Tenable Holdings
$42.98 /

+0.72 (+1.70%)

Periodicals
Facebook's Zuckerberg to work remotely for at least half of next year, WSJ says » 06:12
06/11/21
06/11
06:12
06/11/21
06:12
FB

Facebook

$332.48 /

+2.36 (+0.71%)

Facebook CEO Mark…

Facebook CEO Mark Zuckerberg plans to work remotely for half of the next year, telling staff in a memo this week that working from home makes him "happier and more productive," The Wall Street Journal's Chip Cutter reports. Reference Link

ShowHide Related Items >><<
FB Facebook
$332.48 /

+2.36 (+0.71%)

FB Facebook
$332.48 /

+2.36 (+0.71%)

06/08/21 Tigress Financial
Tigress sees Facebook shares going to $430 within 12 months
06/08/21 Wedbush
Apple WWDC 'all about iOS 15, new Macs,' says Wedbush
06/03/21 Jefferies
Facebook building 'comprehensive SMB tool-set,' says Jefferies
06/03/21 Wedbush
Wedbush expects data privacy to be main focus of Apple's Cook keynote address
FB Facebook
$332.48 /

+2.36 (+0.71%)

FB Facebook
$332.48 /

+2.36 (+0.71%)

FB Facebook
$332.48 /

+2.36 (+0.71%)

FB Facebook
$332.48 /

+2.36 (+0.71%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.